These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Kapur V; Chien CV; Fuess JE; Schwarz ER Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278 [TBL] [Abstract][Full Text] [Related]
4. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Sesti C; Florio V; Johnson EG; Kloner RA Int J Impot Res; 2007; 19(1):55-61. PubMed ID: 16858368 [TBL] [Abstract][Full Text] [Related]
5. [Management of erectile dysfunction in the cardiac patient]. Gratzke C; Becker AJ; Park JW; Reich O; Waldkirch E; Schlenker B; Stief CG Dtsch Med Wochenschr; 2005 Dec; 130(50):2899-903. PubMed ID: 16342015 [No Abstract] [Full Text] [Related]
6. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501 [TBL] [Abstract][Full Text] [Related]
7. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD]. Tatlicioğlu T Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088 [TBL] [Abstract][Full Text] [Related]
8. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. Stief CG; Uckert S; Becker AJ; Truss MC; Jonas U J Urol; 1998 Apr; 159(4):1390-3. PubMed ID: 9507890 [TBL] [Abstract][Full Text] [Related]
9. Comment: acute myocardial infarction after sildenafil citrate ingestion. Raja SG Ann Pharmacother; 2005 Nov; 39(11):1957. PubMed ID: 16204395 [No Abstract] [Full Text] [Related]
10. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012 [TBL] [Abstract][Full Text] [Related]
11. [From the Cochrane Library: Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]. Hamerlynck JV; Middeldorp S; Hooft L Ned Tijdschr Geneeskd; 2007 Sep; 151(38):2101-4. PubMed ID: 17948826 [TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Wong P; Lawrentschuk N; Bolton DM Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 5 inhibitors: are they cardioprotective? Reffelmann T; Kloner RA Cardiovasc Res; 2009 Jul; 83(2):204-12. PubMed ID: 19474180 [TBL] [Abstract][Full Text] [Related]
14. [Intensive anti-platelet treatment: a new viewpoint in reperfusion strategy for ST segment elevation myocardial infarction]. Huo Y; Chen M Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(16):1091-2. PubMed ID: 16796831 [No Abstract] [Full Text] [Related]
17. [What the general practitioner can do to rehabilitate the patient]. Derouet H MMW Fortschr Med; 2005 Mar; 147(9):51-2. PubMed ID: 15794357 [No Abstract] [Full Text] [Related]
18. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. Tinel H; Stelte-Ludwig B; Hütter J; Sandner P BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354 [TBL] [Abstract][Full Text] [Related]
19. PDE-5 inhibitors: current status and future trends. Masson P; Lambert SM; Brown M; Shabsigh R Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042 [TBL] [Abstract][Full Text] [Related]
20. [Good sex inspite of erectile dysfunction. A new PDE-5 inhibitor gives more latitude]. MMW Fortschr Med; 2003 Feb; 145(8):55. PubMed ID: 12661446 [No Abstract] [Full Text] [Related] [Next] [New Search]